Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.42 |
| ▸ | CTSD | P07339 | 3/20 | 0.42 |
| ▸ | PGR | P06401 | 5/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244815 | 0.86 | PGR (0.35) | BACE1BACE2PGR | |
| SCHEMBL8247352 | 0.85 | BACE1 (0.48) | BACE1PGR | |
| SCHEMBL8244505 | 0.84 | BACE1 (0.43) | BACE1PGR | |
| SCHEMBL8238800 | 0.83 | NR1H2 (0.37) | BACE1BACE2 | |
| SCHEMBL10084447 | 0.82 | BACE1 (0.48) | BACE1BACE2CTSDPGR | |
| SCHEMBL10074532 | 0.82 | BACE1 (0.34) | BACE1 | |
| SCHEMBL10074528 | 0.81 | HCAR3 (0.36) | HSD11B1 | |
| SCHEMBL7536095 | 0.78 | BACE1 (0.42) | BACE1BACE2CTSDPGRHSD11B1 | |
| SCHEMBL7531914 | 0.76 | BACE1 (0.44) | BACE1BACE2CTSDPGRHSD11B1 | |
| SCHEMBL13069253 | 0.73 | BACE1 (0.31) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110682-B2 | Preparation and use of compounds as aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110682-B2 | Preparation and use of compounds as aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070010667-A1 | Preparation and use of compounds as aspartyl protease inhibitors | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010667-A1 | Preparation and use of compounds as aspartyl protease inhibitors | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010667-A1 | Preparation and use of compounds as aspartyl protease inhibitors | PRSS1, CTSS, CTSL | BACE1 11/4885BACE2 54/4885CTSD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.